Alopecia associated with ritonavir-boosted atazanavir therapy

被引：3
|
作者：
Torres, Harrys A.
Barnetth, Ben J.
Arduino, Roberto C.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis Infec Control & Employee Hlth, Houston, TX 77030 USA
[2] Univ Texas, Hlth Sci Ctr, Houston Med Sch, Dept Internal Med,Div Infect Dis, Houston, TX USA
来源：
AIDS | 2007年 / 21卷 / 10期
关键词：
D O I：
10.1097/QAD.0b013e3281532b42
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1391 / 1392
页数：2
相关论文
共 50 条
  • [1] Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir
    Rockwood, Neesha
    Mandalia, Sundhiya
    Bower, Mark
    Gazzard, Brian
    Nelson, Mark
    AIDS, 2011, 25 (13) : 1671 - 1673
  • [2] Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
    Nishijima, Takeshi
    Hamada, Yohei
    Watanabe, Koji
    Komatsu, Hirokazu
    Kinai, Ei
    Tsukada, Kunihisa
    Teruya, Katsuji
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Oka, Shinichi
    PLOS ONE, 2013, 8 (10):
  • [3] Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir
    Gutierrez-Valencia, Alicia
    Ruiz-Valderas, Rosa
    Torres-Cornejo, Almudena
    Viciana, Pompeyo
    Espinosa, Nuria
    Castillo-Ferrando, Juan R.
    Lopez-Cortes, Luis F.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (02) : 268 - 273
  • [4] Increased exposure of norethindrone in HIV plus women treated with ritonavir-boosted atazanavir therapy
    DuBois, Barent N.
    Atrio, Jessica
    Stanczyk, Frank Z.
    Cherala, Ganesh
    CONTRACEPTION, 2015, 91 (01) : 71 - 75
  • [5] Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir
    Klein, Cheri E.
    Chiu, Yi-Lin
    Cai, Yan
    Beck, Katrin
    King, Kathryn R.
    Causemaker, Sonja J.
    Doan, Thao
    Esslinger, Hans-Ulrich
    Podsadecki, Thomas J.
    Hanna, George J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (05): : 553 - 562
  • [6] Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers
    Tomaka, F.
    Lefebvre, E.
    Sekar, V.
    Van Baelen, B.
    Vangeneugden, T.
    Vandevoorde, A.
    Miralles, G. Diego
    HIV MEDICINE, 2009, 10 (05) : 318 - 327
  • [7] Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports
    Gallagher, David P.
    Kieran, Jennifer
    Sheehan, Gerard
    Lambert, John
    Mahon, Niall
    Mallon, Patrick W. G.
    CLINICAL INFECTIOUS DISEASES, 2008, 47 (03) : E36 - E38
  • [8] Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin
    Gausi, Kamunkhwala
    Mugerwa, Henry
    Siccardi, Marco
    Montanha, Maiara Camotti
    Lamorde, Mohammed
    Wiesner, Lubbe
    D'Avolio, Antonio
    Mcilleron, Helen
    Wilkins, Edmund
    De Nicolo, Amedeo
    Maartens, Gary
    Khoo, Saye
    Kityo, Cissy
    Denti, Paolo
    Waitt, Catriona
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (05) : 1246 - 1255
  • [9] Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
    Hamada, Yohei
    Nishijima, Takeshi
    Komatsu, Hirokazu
    Teruya, Katsuji
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Oka, Shinichi
    PLOS ONE, 2013, 8 (07):
  • [10] Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use
    Goicoechea, Miguel
    Best, Brookie
    Capparelli, Edmund
    Caperna, Joseph
    Ballard, Craig
    Haubrich, Richard
    AIDS, 2006, 20 (16) : 2127 - 2128
12345